Evidence map›Paper›PMID 39026981›Full record

ArticleFrontiers in oncology2024

Immunotherapy and radiotherapy for older patients with invasive bladder cancer unfit for surgery or chemotherapy: practical proposal by the international geriatric radiotherapy group.

Nam Phong Nguyen, Ulf Lennart Karlsson, Brandi R Page, Monica-Emilia Chirila, Vincent Vinh-Hung, Olena Gorobets, Meritxell Arenas, Mohammad Mohammadianpanah, Seyed Alireza Javadinia, Huan Giap and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Nam Phong NguyenDepartment of Radiation Oncology, Howard University, Washington, DC, United States.
Ulf Lennart KarlssonDepartment of Radiation Oncology, International Geriatric Radiotherapy Group, Washington, DC, United States.
Brandi R PageDepartment of Radiation Oncology, Johns Hopkins University, Baltimore, MD, United States.
Monica-Emilia ChirilaDepartment of Clinical Development, MVision AI, Helsinki, Finland.
Vincent Vinh-HungDepartment of Radiation Oncology, Centre Hospitalier Public du Contentin, Cherbour-en-Contentin, France.
Olena GorobetsDepartment of Oral Surgery, University Hospital of Martinique, Fort-de-France, France.
Meritxell ArenasDepartment of Radiation Oncology, Sant Joan de Reus University Hospital, University of Rovira, I Virgili, Tarragona, Spain.
Mohammad MohammadianpanahColorectal Research Center, Department of Radiation Oncology, Shiraz University of Medical Sciences, Shiraz, Iran.
Seyed Alireza JavadiniaNon-Communicable Diseases Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran.
Huan GiapDepartment of Radiation Oncology, Medical University of South Carolina, Charleston, SC, United States.
Lyndon KimDivision of Neuro-Oncology, Mount Sinai Hospital, New York, NY, United States.
Fabien DutheilDepartment of Radiation Oncology, Clinique Sainte Clotilde, Saint Denis, Reunion, France.
Vedang MurthyTata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
Abba Aji MallumDepartment of Radiation Oncology, University of KwaZulu Natal, Durban, South Africa.
Ghassen TliliDepartment of Urology, University Hospital Center, Sousse, Tunisia.
Zineb DahbiDepartment of Radiation Oncology, Mohammed VI University of Health Sciences, Casablanca, Morocco.
Gokoulakrichenane LoganadaneDepartment of Radiation Oncology, Institut Curie, Paris, France.
Sergio Calleja BlancoDepartment of Oral Maxillofacial Surgery, Howard University, Washington, DC, United States.
Satya BoseDepartment of Radiation Oncology, Howard University, Washington, DC, United States.
Elena NatoliDepartment of Radiation Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Eric LiDepartment of Pathology, Howard University, Washington, DC, United States.
Alessio G MorgantiDepartment of Radiation Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The standard of care for non-metastatic muscle invasive bladder cancer is either radical cystectomy or bladder preservation therapy, which consists of maximal transurethral bladder resection of the tumor followed by concurrent chemoradiation with a cisplatin-based regimen. However, for older cancer patients who are too frail for surgical resection or have decreased renal function, radiotherapy alone may offer palliation. Recently, immunotherapy with immune checkpoint inhibitors (ICI) has emerged as a promising treatment when combined with radiotherapy due to the synergy of those two modalities. Transitional carcinoma of the bladder is traditionally a model for immunotherapy with an excellent response to Bacille Calmette-Guerin (BCG) in early disease stages, and with avelumab and atezolizumab for metastatic disease. Thus, we propose an algorithm combining immunotherapy and radiotherapy for older patients with locally advanced muscle-invasive bladder cancer who are not candidates for cisplatin-based chemotherapy and surgery.

Indexed as

bladder cancerICIinvasiveolderradiotherapy

Identifiers

PMID39026981
PMCPMC11254657

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.